Updates in Immunotherapy for Pancreatic Cancer

被引:0
|
作者
Chick, Robert Connor [1 ]
Pawlik, Timothy M. [1 ]
机构
[1] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
pancreatic cancer; immunotherapy; personalized; tumor microenvironment; immune checkpoint inhibitor; cancer vaccine; T-CELLS; TUMOR MICROENVIRONMENT; CHECKPOINT INHIBITORS; STROMAL INFLAMMATION; NEOADJUVANT THERAPY; OPEN-LABEL; COMBINATION; TRIAL; PEMBROLIZUMAB; FOLFIRINOX;
D O I
10.3390/jcm13216419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit a dysregulated host immune response, PDAC is often characterized by poor immune infiltration and an immune-privileged fibrotic stroma. As understanding of the tumor microenvironment (TME) evolves, novel therapies are being developed to target immunosuppressive mechanisms. Immune checkpoint inhibitors have limited efficacy when used alone or with radiation. Combinations of immune therapies, along with chemotherapy or chemoradiation, have demonstrated promise in preclinical and early clinical trials. Despite dismal response rates for immunotherapy for metastatic PDAC, response rates with neoadjuvant immunotherapy are somewhat encouraging, suggesting that incorporation of immunotherapy in the treatment of PDAC should be earlier in the disease course. Precision therapy for PDAC may be informed by advances in transcriptomic sequencing that can identify immunophenotypes, allowing for more appropriate treatment selection for each individual patient. Personalized and antigen-specific therapies are an increasing topic of interest, including adjuvant immunotherapy using personalized mRNA vaccines to prevent recurrence. Further development of personalized immune therapies will need to balance precision with generalizability and cost.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Immunotherapy updates in pancreatic cancer: are we there yet?
    Gunturu, Krishna Soujanya
    Rossi, Gabriela R.
    Saif, Muhammad Wasif
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (01) : 81 - 89
  • [2] Immunotherapy for pancreatic cancer
    Kotteas, Elias
    Saif, Muhammad Wasif
    Syrigos, Konstantinos
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (08) : 1795 - 1805
  • [3] Immunotherapy for pancreatic cancer: Barriers and breakthroughs
    Torphy, Robert J.
    Zhu, Yuwen
    Schulick, Richard D.
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2018, 2 (04): : 274 - 281
  • [4] Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
    Chick, Robert Connor
    Gunderson, Andrew J.
    Rahman, Shafia
    Cloyd, Jordan M.
    CANCERS, 2023, 15 (15)
  • [5] Immunotherapy for pancreatic cancer: A long and hopeful journey
    Xu, Jian-wei
    Wang, Lei
    Cheng, Yu-gang
    Zhang, Guang-yong
    Hu, San-yuan
    Zhou, Bin
    Zhan, Han-xiang
    CANCER LETTERS, 2018, 425 : 143 - 151
  • [6] Advancing Immunotherapy in Pancreatic Cancer
    Hegazi, Ahmad
    Rager, Lauren Elizabeth
    Watkins, Dean Edward
    Su, Kuo-Hui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (21)
  • [7] Immunotherapy in pancreatic cancer: New hope or mission impossible?
    Jiang, Jiahong
    Zhou, Huaixiang
    Ni, Chao
    He, Xiaoge
    Mou, Yiping
    Huang, Dongsheng
    Yang, Liu
    CANCER LETTERS, 2019, 445 : 57 - 64
  • [8] Advances in immunotherapy for pancreatic ductal adenocarcinoma
    Miyazawa, Motoki
    Katsuda, Masahiro
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-ichi
    Kitahata, Yuji
    Yamaue, Hiroki
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2021, 28 (05) : 419 - 430
  • [9] Dilemma and Challenge of Immunotherapy for Pancreatic Cancer
    Wu, Jia
    Cai, Jianting
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (02) : 359 - 368
  • [10] Pancreatic Cancer and Immunotherapy: A Clinical Overview
    Timmer, Florentine E. F.
    Geboers, Bart
    Nieuwenhuizen, Sanne
    Dijkstra, Madelon
    Schouten, Evelien A. C.
    Puijk, Robbert S.
    de Vries, Jan J. J.
    van den Tol, M. Petrousjka
    Bruynzeel, Anna M. E.
    Streppel, Mirte M.
    Wilmink, Johanna W.
    van Der Vliet, Hans J.
    Meijerink, Martijn R.
    Scheffer, Hester J.
    de Gruijl, Tanja D.
    CANCERS, 2021, 13 (16)